<DOC>
	<DOCNO>NCT00007605</DOCNO>
	<brief_summary>Atrial fibrillation frequently occur cardiac arrhythmia , 1.0-1.5 million case annually . It risk factor congestive heart failure , stroke , 75,000 case latter occur annually patient atrial fibrillation . The safety widely use antiarrhythmic agent group patient , quinidine , call question . This study seek determine whether two agent , amiodarone sotalol , safe effective treatment patient atrial fibrillation .</brief_summary>
	<brief_title>Comparing Effects Amiodarone , Sotalol , Placebo Maintaining Sinus Rhythm Patients With Atrial Fibrillation Converted Sinus Rhythm</brief_title>
	<detailed_description>Primary Hypothesis : The primary objective compare effect amiodarone , sotalol , placebo maintain sinus rhythm patient atrial fibrillation convert sinus rhythm . Secondary Hypotheses : To compare three therapy regard : 1 . Frequency episodes major minor stroke . 2 . Frequency episodes major minor bleeds . 3 . Frequency sudden death , cardiac mortality , total mortality . 4 . Frequency life-threatening pro-arrhythmic reaction . 5 . Frequency episodes congestive heart failure . 6 . Frequency side effect necessitate discontinuation therapy . 7 . Frequency mean duration hospitalization directly relate atrial fibrillation flutter . 8 . Mean change maximal exercise capacity treadmill atrial fibrillation flutter versus sinus rhythm . 9 . Time development sinus rhythm randomization day 28 study . 10 . Mean duration interval occurrences atrial fibrillation flutter day 28 . 11 . The mean ventricular response document electrocardiogram ( ECG ) recording occurrences atrial fibrillation flutter day 28 . 12 . Changes health-related quality life measure SF-36 atrial fibrillation quality life questionnaire . 13 . Time first occurrence atrial fibrillation flutter day 28 cessation treatment due adverse drug reaction randomization . Intervention : Patients randomize amiodarone ( 400mg bid 14 day , 400mg qam d200mg qhs 14 day , 300mg qd 48 week , 200mg qd ) , sotalol 80mg bid 7 day 160mg bid thereafter ) placebo . Primary Outcomes : The time day 28 randomization first occurrence atrial fibrillation flutter . Failure time set 0 day patient fail cardiovert day 28 . Study Abstract : Atrial fibrillation frequently occur cardiac arrhythmia , 1.0-1.5 million case annually . It risk factor congestive heart failure , stroke , 75,000 case latter occur annually patient atrial fibrillation . The safety widely use antiarrhythmic agent group patient , quinidine , call question . This study seek determine whether two agent , amiodarone sotalol , safe effective treatment patient atrial fibrillation . All patient atrial fibrillation continuously great 72 hour . Background medication include warfarin anticoagulation digoxin plus diltiazem verapamil heart rate control . If warfarin contraindicate , leave atrial thrombus must exclude transesophageal echo ( TEE ) aspirin 325 mg QD may use . Patients randomly assign receive sotalol ( 80 mg bid 7 day 160 mg bid thereafter ) , amiodarone ( 400 mg bid 14 day , 400 mg qam 200 mg qhs 14 day , 300 mg qd 48 week , 200 mg qd ) placebo . Treatment assignment stratify participate hospital , whether patient ischemic heart disease whether patient symptomatic . After randomization , patient stay drug rate control sinus rhythm restore anticoagulation two month sinus rhythm restore . After four week , patient remain atrial fibrillation undergo DC cardioversion . Those patient warfarin must undergo another TEE within 48 hour prior cardioversion . Patients heart rhythm monitor transtelephonically every week occurrences atrial fibrillation flutter document twice within 24 hour . In case document atrial fibrillation flutter occurrence , patient re-anticoagulated appropriate time subject DC cardioversion restore sinus rhythm . Patients sinus rhythm follow end study . Patients relapse AF follow minimum one year relapse , whichever later . Assuming 35 % patient placebo , 50 % sotalol , 60 % amiodarone remain normal sinus rhythm end one year , sample size 706 patient , 279 amiodarone , 279 sotalol , 148 placebo ( 85 % power two-sided overall alpha level 0.05 set three pairwise comparison ) need group difference statistically significant .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Death , Sudden</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Sotalol</mesh_term>
	<criteria>Patients atrial fibrillation continuously great 72 hour .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>amiodarone</keyword>
	<keyword>atrial fibrillation convert sinus rhythm</keyword>
	<keyword>cardiac mortality</keyword>
	<keyword>major minor bleeds</keyword>
	<keyword>sinus rhythm</keyword>
	<keyword>sotalol</keyword>
</DOC>